Hedeker Wealth LLC held its stake in CME Group Inc. (NASDAQ:CME) during the second quarter, Holdings Channel reports. The firm owned 3,400 shares of the company’s stock at the end of the second quarter. Hedeker Wealth LLC’s holdings in CME Group were worth $331,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of CME. Bank of Montreal Can bought a new stake in CME Group during the second quarter valued at approximately $35,643,000. Legal & General Group Plc increased its stake in CME Group by 2.0% in the first quarter. Legal & General Group Plc now owns 1,391,482 shares of the company’s stock valued at $133,643,000 after buying an additional 27,322 shares in the last quarter. AMP Capital Investors Ltd increased its stake in CME Group by 10.6% in the first quarter. AMP Capital Investors Ltd now owns 278,973 shares of the company’s stock valued at $26,661,000 after buying an additional 26,751 shares in the last quarter. UMB Bank N A MO increased its stake in CME Group by 5.8% in the second quarter. UMB Bank N A MO now owns 177,713 shares of the company’s stock valued at $17,309,000 after buying an additional 9,775 shares in the last quarter. Finally, Strs Ohio increased its stake in CME Group by 5.2% in the second quarter. Strs Ohio now owns 234,783 shares of the company’s stock valued at $22,867,000 after buying an additional 11,596 shares in the last quarter. 79.89% of the stock is owned by institutional investors and hedge funds.
Shares of CME Group Inc. (NASDAQ:CME) traded down 1.62% on Monday, hitting $103.73. The company’s stock had a trading volume of 884,805 shares. The company has a market cap of $35.15 billion, a price-to-earnings ratio of 26.19 and a beta of 0.83. CME Group Inc. has a 52 week low of $81.87 and a 52 week high of $110.35. The stock’s 50 day moving average is $106.48 and its 200-day moving average is $99.70.
CME Group (NASDAQ:CME) last released its quarterly earnings results on Thursday, July 28th. The company reported $1.14 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.11 by $0.03. The company had revenue of $906 million for the quarter, compared to analysts’ expectations of $897.84 million. CME Group had a return on equity of 6.83% and a net margin of 38.22%. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.95 earnings per share. On average, equities research analysts anticipate that CME Group Inc. will post $4.43 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Monday, September 26th. Stockholders of record on Friday, September 9th were issued a dividend of $0.60 per share. The ex-dividend date was Wednesday, September 7th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 2.31%. CME Group’s dividend payout ratio (DPR) is presently 60.61%.
A number of equities analysts have recently issued reports on the company. Credit Agricole SA cut their target price on CME Group from $100.00 to $95.00 and set an “underperform” rating for the company in a research note on Thursday, July 14th. Keefe, Bruyette & Woods increased their target price on CME Group from $99.00 to $103.00 and gave the stock a “market perform” rating in a research note on Friday, July 29th. Deutsche Bank AG upped their price target on CME Group from $111.00 to $112.00 and gave the stock a “buy” rating in a report on Friday, August 5th. Barclays PLC lowered their price target on CME Group from $100.00 to $99.00 and set an “equal weight” rating on the stock in a report on Friday, July 29th. Finally, Zacks Investment Research upgraded CME Group from a “hold” rating to a “buy” rating and set a $116.00 price target on the stock in a report on Thursday, August 4th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $103.27.
In related news, CEO Phupinder Gill sold 30,002 shares of the business’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $110.00, for a total transaction of $3,300,220.00. Following the sale, the chief executive officer now owns 116,222 shares of the company’s stock, valued at $12,784,420. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Ronald A. Pankau sold 400 shares of the business’s stock in a transaction that occurred on Thursday, August 11th. The stock was sold at an average price of $103.32, for a total value of $41,328.00. Following the sale, the director now directly owns 4,382 shares in the company, valued at approximately $452,748.24. The disclosure for this sale can be found here. Insiders own 0.61% of the company’s stock.
CME Group Company Profile
CME Group Inc is a provider of products across all major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. The Company’s products include both exchange-traded and privately negotiated futures and options contracts and swaps. The Company connects buyers and sellers together through its CME Globex electronic trading platform across the globe and its open outcry trading facilities in Chicago and New York City.
Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME).
Receive News & Ratings for CME Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group Inc. and related companies with MarketBeat.com's FREE daily email newsletter.